ADYNOVATE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ADYNOVATE
Generic name
ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED
Manufacturer
Takeda Pharmaceuticals Amercia, Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
ef290433-997f-4e98-86d6-42f6a99d6d18
SPL ID
24de100e-5b4b-4bc7-ba3a-6dc768df9eb0
Version
24
Effective date
2026-05-28
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:17

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, have been reported. Should symptoms occur, discontinue treatment with ADYNOVATE and administer appropriate treatment. ( 5.1 ) Development of factor VIII neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including anaphylaxis, have been reported with ADYNOVATE. Hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, pruritus, and nausea and vomiting. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of ADYNOVATE. Monitor patients regularly for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests. Perform an assay that measures factor VIII inhibitor concentration if the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled with expected dose. 5.3 Monitoring Laboratory Tests Monitor plasma factor VIII activity by performing a validated one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained [see Dosage and Administration (2) ]. Monitor for the development of factor VIII inhibitors. Perform the Bethesda inhibitor assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with the expected dose of ADYNOVATE, use Bethesda Units (BU) to determine inhibitor levels.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions reported in ≥1% of patients were cough, headache, diarrhea, vomiting, rash, nausea, urticaria, and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety database described in this section reflects exposure of ADYNOVATE in 478 previously treated patients (PTPs) and previously untreated patients (PUPs) with severe hemophilia A (factor VIII less than 1% of normal), who received at least one dose of ADYNOVATE in 7 clinical studies [see Immunogenicity (12.6) and Clinical Studies (14) ] . The total number of infusions within the safety database is 92173. Table 3 lists the adverse reactions reported during clinical studies. The most common adverse reactions (≥1% of patients) were cough, headache, diarrhea, vomiting, rash, nausea, urticaria, and dizziness. Table 3: Adverse Reactions Reported for ADYNOVATE Pooled safety analysis from 7 clinical studies. MedDRA System Organ Class Adverse Reaction Number of Patients n (%) (N=478) a The event of hypersensitivity was a mild transient non-serious rash, occurring in one 2-year old patient who had developed a previous rash while on ADYNOVATE. Gastrointestinal Disorders Diarrhea 38 (8%) Vomiting 26 (5%) Nausea 8 (2%) Respiratory, Thoracic and Mediastinal Disorders Cough 50 (10%) Eye Disorders Ocular Hyperaemia 3 (0.6%) Immune System Disorder Hypersensitivity a 2 (0.4%) Nervous System Disorders Headache 41 (9%) Dizziness 7 (1%) Skin and Subcutaneous Tissue Disorders Rash 16 (3%) Urticaria 9 (2%) Rash Pruritic 1 (0.2%) Eyelid Rash 1 (0.2%) Vascular Disorders Flushing 1 (0.2%) Investigations Eosinophil Count Increased 2 (0.4%) Injury, Poisoning and Procedural Complications Infusion Related Reaction 2 (0.4%) Two cases of acute pancreatitis, with no precipitating cause identified in one case, were reported in adults during an extension study of the clinical trial which evaluated 216 patients. Administration of ADYNOVATE continued and both cases resolved. 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Immune System Disorders: Anaphylactic Reaction

adverse reactions table

<table width="90%" ID="table3"><caption>Table 3: Adverse Reactions Reported for ADYNOVATE<footnote>Pooled safety analysis from 7 clinical studies.</footnote></caption><col width="35%" align="left" valign="top"/><col width="30%" align="center" valign="top"/><col width="35%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" align="center">MedDRA System Organ Class</th><th styleCode="Rrule" align="center">Adverse Reaction</th><th styleCode="Rrule">Number of Patients n (%) (N=478)</th></tr></thead><tfoot><tr><td align="left" colspan="3"><sup>a</sup> The event of hypersensitivity was a mild transient non-serious rash, occurring in one 2-year old patient who had developed a previous rash while on ADYNOVATE.</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="3">Gastrointestinal Disorders</td><td styleCode="Rrule">Diarrhea</td><td styleCode="Rrule">38 (8%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Vomiting</td><td styleCode="Rrule" align="center">26 (5%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Nausea</td><td styleCode="Rrule" align="center">8 (2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Respiratory, Thoracic and Mediastinal Disorders</td><td styleCode="Rrule">Cough</td><td styleCode="Rrule">50 (10%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Eye Disorders</td><td styleCode="Rrule">Ocular Hyperaemia</td><td styleCode="Rrule">3 (0.6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Immune System Disorder</td><td styleCode="Rrule">Hypersensitivity<sup>a</sup></td><td styleCode="Rrule">2 (0.4%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="2">Nervous System Disorders</td><td styleCode="Rrule Botrule">Headache</td><td styleCode="Rrule Botrule">41 (9%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Dizziness</td><td styleCode="Rrule" align="center">7 (1%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="4">Skin and Subcutaneous Tissue Disorders</td><td styleCode="Rrule Botrule">Rash</td><td styleCode="Rrule Botrule">16 (3%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Urticaria</td><td styleCode="Rrule" align="center">9 (2%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Rash Pruritic</td><td styleCode="Rrule" align="center">1 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule" align="center">Eyelid Rash</td><td styleCode="Rrule" align="center">1 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Vascular Disorders</td><td styleCode="Rrule">Flushing</td><td styleCode="Rrule">1 (0.2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Investigations</td><td styleCode="Rrule">Eosinophil Count Increased</td><td styleCode="Rrule">2 (0.4%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Injury, Poisoning and Procedural Complications</td><td styleCode="Rrule">Infusion Related Reaction</td><td styleCode="Rrule">2 (0.4%)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.